Biotech · Private company · San Diego, CA, US
Kintara Therapeutics, Inc.
Track this companyFree. Adds Kintara Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials42 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- REM-001 photodynamic therapyPhase 2 · Cutaneous Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- VAL-083 (Dianhydrogalactitol)Phase 2 · GliomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 12, 2024ClinicalTrials.gov NCT05374915 · fetched Nov 12, 2026
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaPHASE2_PHASE3 · RECRUITING · started Jul 30, 2019ClinicalTrials.gov NCT03970447 · fetched Nov 12, 2026
- Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent SettingPHASE2 · COMPLETED · started Jan 20, 2017ClinicalTrials.gov NCT02717962 · fetched Nov 12, 2026
- Safety Study of VAL-083 in Patients With Recurrent Malignant GliomaPHASE1_PHASE2 · COMPLETED · started Oct 1, 2011ClinicalTrials.gov NCT01478178 · fetched Nov 12, 2026
NIH awards1
- An Open-Labeled, Single Arm Phase 2 Efficacy and Safety Study of REM-001 Photodynamic Therapy (PDT) for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)Fiscal year 2024 · $745.3KNIH RePORTER 5R44CA281615-02 · fetched Nov 12, 2026